Important information will be presented regarding target blood hemoglobin concentrations and clinical outcomes in patients with chronic kidney disease during a session at the American Society of Nephrology’s 39th Annual Meeting and Scientific Exposition in San Diego, CA on Saturday, November 18.
In the session, Drs. Tilman Drueke and Ajay Singh will be presenting data from two clinical trials published this week in The New England Journal of Medicine. Each randomized clinical trial examines the outcomes in patients with chronic kidney disease treated with erythropoietic agents at different target hemoglobin levels. The session, entitled ?Clinical Trials: Defining Target Hemoglobin in CKD,? will be held in Hall D of the San Diego Convention Center from 10:00 am – Noon.
The ASN will hold a News Briefing directly following the session in Room 12 of the San Diego Convention Center. Drs. Drueke and Singh will be available for comment, as will the following representatives from the ASN: Thomas DuBose, MD, FASN, President; William Henrich, MD, FASN, President-Elect; and Dr. Jonathan Himmelfarb, MD, Chair, Public Policy Board.
The ASN is a not-for-profit organization of 9,500 physicians and scientists dedicated to the study of nephrology and committed to providing a forum for the promulgation of information regarding the latest research and clinical findings on kidney diseases. ASN?s Renal Week 2006, the largest nephrology meeting of its kind, will provide a forum for 10,000 nephrologists, to discuss the latest findings in renal research and engage in educational sessions relating advances in the care of patients with kidney and related disorders from November 14-19 at the San Diego Convention Center in San Diego, CA.